National Institutes of Health to Consider Exclusive Start-up Option License for Neuroprotectant Oligodeoxynucleotides

Summary

The National Institutes of Health is seeking to grant an exclusive start-up option license to practice certain inventions related to oligodeoxynucleotides as neuroprotectants for cerebral and other ischemic injuries, as outlined in several patent applications and granted patents filed by the NIH.